Pharminent

AbbVie’s rheumatoid arthritis drug succeeds in late-stage trial

(Reuters) – U.S. drugmaker AbbVie Inc said on Wednesday its drug to treat moderate-to-severe rheumatoid arthritis met the main goal in a late-stage study.

http://www.reuters.com/article/us-abbvie-study-idUSKBN18Y1M9

Filed under: Arthritis